A subcentimeter duodenal neuroendocrine neoplasm with a liver metastasis upgraded to G3: a case report.
Duodenal neuroendocrine neoplasm
High grade
Intratumor heterogeneity
Liver metastasis
Journal
Surgical case reports
ISSN: 2198-7793
Titre abrégé: Surg Case Rep
Pays: Germany
ID NLM: 101662125
Informations de publication
Date de publication:
19 Mar 2021
19 Mar 2021
Historique:
received:
21
01
2021
accepted:
10
03
2021
entrez:
20
3
2021
pubmed:
21
3
2021
medline:
21
3
2021
Statut:
epublish
Résumé
Although duodenal neuroendocrine neoplasms (DuNENs) usually have indolent phenotypes, some DuNENs exhibit aggressive clinical manifestations. Tumor size > 1 cm, lymph node metastasis, and high grade have been associated with poor prognosis. However, preoperative risk evaluation is often difficult, because Ki-67 index on biopsy is frequently underestimated due to the intratumor heterogeneity. Here, we present a case of a subcentimeter DuNEN with a low Ki-67 index on endoscopic biopsy, who developed lymph node metastasis and high-grade liver metastasis. The patient was a 52-year-old female who presented an epigastric pain. Esophagogastroduodenoscopy revealed a duodenal submucosal lesion with a size of 8 mm. The endoscopic biopsy showed DuNEN with a Ki-67 index of 3.3% (G2 categorized by the World Health Organization 2019 classification). We performed an open partial duodenectomy with adjacent lymph node dissection. Pathological examination of the resected specimens revealed a Ki-67 index of 13.5% (G2) in the "hot spot" and lymph node metastasis. A hepatic low-density area detected on preoperative contrast-enhanced computed tomography appeared to be a liver metastasis on postoperative gadoxetic acid-enhanced magnetic resonance imaging. Subsequently, we performed a laparoscopic partial hepatectomy. Pathological examination of the liver specimen showed a metastatic neuroendocrine tumor with a Ki-67 index of 27.5% (NET-G3). The patient has been alive for 14 months since the hepatectomy. This case shows the possibility of high malignant potential of DuNEN even if the primary lesion is < 1 cm and has a low Ki-67 index on biopsy.
Sections du résumé
BACKGROUND
BACKGROUND
Although duodenal neuroendocrine neoplasms (DuNENs) usually have indolent phenotypes, some DuNENs exhibit aggressive clinical manifestations. Tumor size > 1 cm, lymph node metastasis, and high grade have been associated with poor prognosis. However, preoperative risk evaluation is often difficult, because Ki-67 index on biopsy is frequently underestimated due to the intratumor heterogeneity. Here, we present a case of a subcentimeter DuNEN with a low Ki-67 index on endoscopic biopsy, who developed lymph node metastasis and high-grade liver metastasis.
CASE PRESENTATION
METHODS
The patient was a 52-year-old female who presented an epigastric pain. Esophagogastroduodenoscopy revealed a duodenal submucosal lesion with a size of 8 mm. The endoscopic biopsy showed DuNEN with a Ki-67 index of 3.3% (G2 categorized by the World Health Organization 2019 classification). We performed an open partial duodenectomy with adjacent lymph node dissection. Pathological examination of the resected specimens revealed a Ki-67 index of 13.5% (G2) in the "hot spot" and lymph node metastasis. A hepatic low-density area detected on preoperative contrast-enhanced computed tomography appeared to be a liver metastasis on postoperative gadoxetic acid-enhanced magnetic resonance imaging. Subsequently, we performed a laparoscopic partial hepatectomy. Pathological examination of the liver specimen showed a metastatic neuroendocrine tumor with a Ki-67 index of 27.5% (NET-G3). The patient has been alive for 14 months since the hepatectomy.
CONCLUSIONS
CONCLUSIONS
This case shows the possibility of high malignant potential of DuNEN even if the primary lesion is < 1 cm and has a low Ki-67 index on biopsy.
Identifiants
pubmed: 33742297
doi: 10.1186/s40792-021-01155-1
pii: 10.1186/s40792-021-01155-1
pmc: PMC7979845
doi:
Types de publication
Journal Article
Langues
eng
Pagination
72Références
Korean J Gastroenterol. 2020 Nov 25;76(5):251-255
pubmed: 33234773
JAMA Oncol. 2017 Oct 1;3(10):1335-1342
pubmed: 28448665
Neuroendocrinology. 2018;106(2):158-166
pubmed: 28494461
Neuroendocrinology. 2020;110(7-8):616-629
pubmed: 31557757
Am J Surg Pathol. 2011 Jun;35(6):853-60
pubmed: 21566513
Cancer. 2003 Feb 15;97(4):934-59
pubmed: 12569593
Endocr Relat Cancer. 2020 Mar;27(3):R67-R77
pubmed: 31846429
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
Clin Cancer Res. 2016 Feb 15;22(4):1011-7
pubmed: 26482044
Ann Surg Oncol. 2018 Oct;25(11):3200-3206
pubmed: 30054824
Medicine (Baltimore). 2019 Jun;98(23):e15885
pubmed: 31169696
Ann Surg Oncol. 2018 Feb;25(2):528-534
pubmed: 29164413